Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and OpenLabel Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira (R); RP) in Patients (pts) with Active Rheumatoid Arthritis (RA) Genovese, M. C., Glover, J., Matsunaga, N., Chisholm, D., Alten, R. WILEY. 2017
View details for Web of Science ID 000411824106303